Grifols, S.A. (NASDAQ:GRFS – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 3,455,645 shares, a drop of 45.5% from the July 15th total of 6,340,082 shares. Based on an average daily volume of 917,661 shares, the short-interest ratio is currently 3.8 days. Currently, 0.5% of the company’s shares are short sold.
Analyst Ratings Changes
A number of analysts have issued reports on GRFS shares. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings downgraded Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $10.00.
Get Our Latest Stock Report on GRFS
Grifols Stock Down 0.1%
Grifols Dividend Announcement
The business also recently disclosed a special dividend, which was paid on Thursday, July 9th. Stockholders of record on Thursday, July 2nd were given a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio is currently 42.11%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Flat Footed LLC grew its position in shares of Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock worth $11,007,000 after buying an additional 287,867 shares in the last quarter. Norges Bank acquired a new stake in Grifols in the fourth quarter valued at approximately $18,139,000. Quantinno Capital Management LP lifted its stake in Grifols by 42.0% in the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after acquiring an additional 104,418 shares during the last quarter. Brandes Investment Partners LP lifted its stake in Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Grifols by 15.4% during the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after acquiring an additional 104,850 shares in the last quarter.
About Grifols
Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.
The company operates three main business units.
Featured Stories
- Five stocks we like better than Grifols
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
